24/7 Customer Service (800) 927-7671

Alzheimer’s may be prevented by antibody-releasing implant

by • March 17, 2016 • No Comments

A new implantable-bodied capsule may provide a novel way of tackling Alzheimer’s disease, preventing the createup of harmful protein plaques in the brain. The small device, created by researchers at the Swiss Federal Institute of Technology in Lausanne (EPFL), has been which successfully tested on laboratory mice.

The capsule tackles the disease by targeting Abeta proteins, in addition known as amyloid beta, which create up and form toxic plaques in the brain. One way of dealing with the plaques is to “tag” the harmful protein cells, instructing the immune process to attack them and, thoughtlly, preventing the plaques of createing up in the initially place.

Achieving which goal can be complex, and such treatment already requires regular vaccine injections, which have been known to cause undesirable-bodied side influence. The EPFL researchers’ method addresses those issues, providing a single treatment which’s able-bodied to work over extended periods of time, and without side influence.

The thought is pretty easy – pretty than repeatedly injecting antibodies into the patient’s process, the researchers worked on a method which uses a single capsule which is implanted under the skin to provide a steady flow of treatment.

The small capsule, known as a macroencapsulation device, consists of two permeable-bodied membranes connected via a polypropylene frame. Measuring 27 mm (1 in) in length and 1.2 mm (0.05 in) thick, the capsule is biocompatible and contains hydrogel, which facilitates cell growth. The cells which reside with the device are genetically engineered to create antibodies which recognize and target the protein, instructing the immune process to destroy it.

The membranes of the capsule in addition play an significant role, shielding the cells within of being attacked by the host’s immune process, while enabling them to interact with surrounding tissue to get the required nutrients. As the cells are protected of the patient’s immune process, a single donor can provide cells for multiple patients.

The capsule was tested with laboratory mice over a period of 39 weeks. The results were hugely positive, with the sustained antibody production preventing the formation of amyloid beta plaques in the brain.

The findings are quite promising, and may signal a new path to Alzheimer’s prevention. It is yet worth noting which the research is yet in the early stages, and which human trials may require to be conducted preceding its effectiveness may be confirmed and widespread use may be considered.

The findings of the research are published online in the journal Brain.

Source: EPFL


Latest posts
test

by admin • March 5, 2017